Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nested Case-Control Study of Interstitial Lung Disease Risk in NSCLC Patients Treated With or Without Gefitinib
jRCT1080220403Phase 4
- Sponsor
- AstraZeneca
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Relative risk of interstitial lung disease associated with gefitinib and Risk factors for interstitial lung disease.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1080220403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080220403.